Fairfax, VA, United States
Fairfax, VA, United States

Time filter

Source Type

PHOENIX--(BUSINESS WIRE)--Arizona Oncology, one of the largest medical groups in Arizona and a practice in The US Oncology Network, has demonstrated compliance with the standards of the American Society for Radiation Oncology (ASTRO) Accreditation Program for Excellence (APEx®), effective May 1, 2017 for a four-year accreditation of its radiation oncology services. APEx is an independent radiation oncology practice accreditation program developed by ASTRO based on a comprehensive set of sixteen evidence-based standards of radiation oncology practice. The sixteen standards are focused on five pillars of patient care: “Arizona Oncology is pleased to receive APEx accreditation at our Arizona Oncology Radiation Treatment Centers in Phoenix from the premier radiation oncology society in the world, ” said Jerry Lucas, MD, radiation oncologist, Arizona Oncology. “Evaluating our processes in relation to ASTRO’s high standards, including standards for safety and quality, validates our practices and recognizes the efforts of our radiation oncology team to deliver patient-centered radiation oncology care.” Accreditation through APEx is a rigorous, voluntary, multi-step process that can take up to one year to complete. Each center seeking APEx accreditation must have its policies and procedures evaluated using objective, verifiable expectations for performance in radiation oncology. It must demonstrate its commitment to high standards of safety and quality in the practice of radiation oncology and that it practices patient-centered care by promoting effective communication, coordinating treatment, and engaging patients and their families as partners in care. APEx has a distinctive program structure that includes both a self-assessment process and a facility visit conducted by a medical physicist and a radiation oncologist, radiation therapist, nurse, dosimetrist, nurse practitioner, physician assistant or practice administrator. APEx integrates Maintenance of Certification (MOC) templates that promote value and efficiency for physicians and final evaluation reports that link standards and performance to quality improvement resources. APEx applicants also have access to a library of quality improvement practice management tools to facilitate a culture of safety. APEx reflects competencies and practices identified and endorsed in the 2012 ASTRO publication Safety is No Accident: A Framework for Quality Radiation Oncology and Care. “ASTRO is proud to recognize Arizona Oncology for achieving APEx accreditation,” said ASTRO Chair David C. Beyer, MD, FASTRO. “Arizona Oncology has demonstrated a commitment to providing their patients with safe, high-quality radiation therapy services.” Arizona Oncology is one of the largest medical groups in Arizona. With more than 75 practicing physicians devoted exclusively to providing comprehensive, compassionate and high-quality cancer care, Arizona Oncology specializes in Medical, Gynecologic and Radiation Oncology, Hematology, Stem Cell Transplant, Research, Genetic Risk Assessment and patient ancillary programs. The physicians and their staff treat patients in many communities throughout the state including: Deer Valley, East Valley (Tempe), Estrella, Flagstaff, Glendale, Green Valley, Nogales, Peoria, Phoenix, Prescott Valley, Safford, Scottsdale, Sedona, and Tucson. Arizona Oncology believes it is beneficial to provide cancer therapies in a community setting, close to patients' homes and support systems. The physicians are supported by a talented clinical team sensitive to the needs of cancer patients and their caregivers. For more information, visit ArizonaOncology.com. Arizona Oncology is an affiliate of The US Oncology Network (“The Network”). This collaboration unites Arizona Oncology with more than 1,400 independent physicians dedicated to delivering value-based, integrated care for patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The US Oncology Network is supported by McKesson Specialty Health, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. Arizona Oncology also participates in clinical trials through US Oncology Research, which has played a role in nearly 70 FDA-approved cancer therapies, approximately one-third of all cancer therapies approved by the FDA to date. For more information, visit www.usoncology.com. ASTRO is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology • Biology • Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (http://www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit www.astro.org.


News Article | March 8, 2017
Site: globenewswire.com

NASHUA, N.H., March 08, 2017 (GLOBE NEWSWIRE) -- iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and twelve months ended December 31, 2016. “Our fourth quarter revenue grew 15% sequentially compared to the third quarter of 2016, reflecting improved performance in our cancer therapy business,” said Ken Ferry, Chief Executive Officer.  “This included a stronger quarter for IORT system and balloon applicator sales, as result of greater sales activity, and increased procedure volume in both the U.S. and international markets.  We also had our strongest quarter of the year adding new customers in our skin electronic brachytherapy business.  Our cancer detection team continues to make good progress with the development of software tools that enhance the workflow and interpretation of 3D tomosynthesis breast exams.  We expect these tools to be a major growth opportunity for the Company over time.  Currently, these products are available in certain international markets and are pending FDA clearance in the United States.” Mr. Ferry added, “We remain confident in the longer term outlook for our business.  In the fourth quarter we made additional key investments in support of our goal of obtaining a CPT 1 reimbursement code for skin electronic brachytherapy, added sales personnel to support future growth in the skin therapy and cancer detection software markets, and had a robust presence at the two most important medical meetings that we attend, ASTRO and RSNA.  Also, in January 2017, we strengthened our balance sheet with the sale of our MRI CAD business for $3.2 million.” Revenue:  Total revenue for the fourth quarter of 2016 decreased 9% to $6.9 million from $7.6 million in the fourth quarter of 2015, reflecting a 15% increase in product revenue and a 21% decrease in service revenue.  The decrease in the Company’s revenue in the fourth quarter of 2016 was primarily driven by the comparable decline of therapy service revenue associated with the treatment of non-melanoma skin cancer in the United States.  On a sequential quarter basis, total revenue for the fourth quarter of 2016 increased 15% from $6.0 million in the third quarter of 2016.  Service revenue for the fourth quarter of 2016 was approximately 57% of total revenues compared to approximately 65% of total revenues in the fourth quarter of 2015. Cancer detection revenue for the fourth quarter of 2016 decreased by 3%, which includes digital mammography, breast density, MRI and CT CAD platforms, as well as the associated service revenue.  Therapy revenue decreased by 17%, which includes Xoft® Axxent® Electronic Brachytherapy System® product sales, as well as the associated service revenue. Gross Profit:  Gross profit for the fourth quarter of 2016 decreased to $4.5 million, or 65% of revenue, from $5.3 million, or 70% of revenue, for the fourth quarter of 2015. Operating Expenses:  Total operating expenses for the fourth quarter of 2016 increased to $7.8 million from $7.6 million for the fourth quarter of 2015. The year-over-year increase reflects investments in strategic growth drivers, partially offset by the Company’s cost reduction initiatives which were implemented in 2015. GAAP Net Loss:  Net loss for the fourth quarter of 2016 was $(3.3) million, or $(0.20) per share, compared with net loss of $(2.4) million, or $(0.15) per share, for the fourth quarter of 2015. Non-GAAP Adjusted EBITDA:  Non-GAAP adjusted EBITDA, a non-GAAP financial measure as defined below, was a loss $(2.0) million for the fourth quarter of 2016, compared with non-GAAP adjusted EBITDA loss of $(1.1) million for the fourth quarter of 2015. Non-GAAP Adjusted Net Income/Loss: Non-GAAP adjusted net loss, as defined below, for the fourth quarter of 2016 was $(3.2) million, or $(0.20) per share, compared with a non-GAAP adjusted net loss of $(2.2) million, or $(0.14) per share, for the fourth quarter of 2015. Cash and Cash Equivalents:  As of December 31, 2016, the Company had cash and cash equivalents of $8.6 million, compared with $15.3 million as of December 31, 2015. The Company used $1.6 million of cash from operating activities in the fourth quarter of 2016. Revenue:  Total revenue for fiscal year 2016 decreased 37% to $26.3 million from $41.6 million for fiscal year 2015, reflecting a 26% decrease in product revenue and a 42% decrease in service revenue. The decrease in the Company’s revenue in fiscal year 2016 was primarily driven by declining revenues related to the treatment of non-melanoma skin cancer in the United States. The decrease was also driven by a reduction of approximately $2.1 million of MRI-CAD product sales due to the Company’s exclusive distribution partner exercising its right in August 2015 to a fully paid-up license to distribute the software. This provided the Company with a cash payment of $2.0 million during the third quarter of 2015 that is being amortized over the term of the contract through July 2017.  Service revenue for fiscal year 2016 was approximately 60% of total revenues compared to approximately 66% of total revenues for fiscal year 2015. Cancer detection revenue for fiscal year 2016 decreased by 11%, which includes digital mammography, breast density, MRI and CT CAD platforms, as well as the associated service revenue.  When adjusted for the $2.1 million reduction in MRI-CAD product revenue, cancer detection revenues were essentially flat compared to fiscal year 2015.  Therapy revenue for fiscal year 2016 decreased by 59%, which includes Xoft® Axxent® Electronic Brachytherapy System® product sales, as well as the associated service revenue. Gross Profit:  Gross profit for fiscal year 2016 decreased to $18.5 million, or 70% of revenue, from $29.4 million, or 71% of revenue, for fiscal year 2015.  Gross profit for fiscal year 2016 included a U.S. medical device excise tax refund of $0.5 million. Operating Expenses:  Total operating expenses for fiscal year 2016 decreased to $28.5 million from $59.4 million for fiscal year 2015, which included $27.4 million of goodwill and long-lived asset impairment. Operating expenses for fiscal year 2015 were $32.0 million excluding the impairment.  The year-over-year decline reflects the effect of the Company’s cost reduction initiatives implemented in 2015. GAAP Net Loss:  Net loss for fiscal year 2016 was $(10.1) million, or $(0.63) per share, compared with net loss of $(32.5) million, or $(2.07) per share, for fiscal year 2015. Non-GAAP Adjusted EBITDA:  Non-GAAP adjusted EBITDA, a non-GAAP financial measure as defined below, was a loss of $(5.3) million for fiscal year 2016, compared with non-GAAP adjusted EBITDA of $3.9 million, or 9% of revenue, for fiscal year 2015. Non-GAAP Adjusted Net Income/Loss:  Non-GAAP adjusted net loss, as defined below, for fiscal year 2016 was $(9.8) million, or $(0.63) per share, compared with a non-GAAP adjusted net loss of $(2.2) million, or $(0.14) per share, for fiscal year 2015. iCAD management will host a conference call today at 4:30 p.m. Eastern Time to discuss the financial results and provide a company update.  The dial-in numbers are (855) 217-4501 for domestic callers and (716) 220-9431 for international callers.  The conference ID is 57732542.  A live webcast of the conference call will be available online at www.icadmed.com. A replay of the webcast will remain on the Company’s website until the Company releases its first quarter 2017 financial results.  In addition, a telephonic replay of the conference call will be available until March 15, 2017.  The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers.  The replay conference ID is 57732542. Use of Non-GAAP Financial Measures In its quarterly news releases, conference calls, slide presentations or webcasts, the Company may use or discuss non-GAAP financial measures as defined by SEC Regulation G.  The GAAP financial measures most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements.  When analyzing the Company's operating performance, investors should not consider these non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP.  The Company's quarterly news releases containing such non-GAAP reconciliations can be found on the Investors section of the Company's website at www.icadmed.com. iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes.  iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers.  iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue.  The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers.  The comprehensive iCAD technology platforms include advanced hardware and software, as well as management services designed to support cancer detection and radiation therapy treatments.  For more information, visit www.icadmed.com or www.xoftinc.com. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995 Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission.  The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”, “consider”, “project”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements.  Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made.  The Company is under no obligation to provide any updates to any information contained in this release.  For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, including the 10-K for the year ended December 31, 2015, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov. RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO COMPARABLE GAAP MEASURES (Unaudited, in thousands, except per share amounts) The following is a reconciliation of the non-GAAP financial measures used by the Company to describe the Company's financial results determined in accordance with United States generally accepted accounting principles (GAAP).  An explanation of these measures is also included below under the heading "Explanation of Non-GAAP Financial Measures." While management believes that these non-GAAP financial measures provide useful supplemental information to investors regarding the underlying performance of the Company's business operations, investors are reminded to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP.  In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP financial measures used by other companies, and management may utilize other measures to illustrate performance in the future.  Non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with the Company's results of operations as determined in accordance with GAAP. The Company reports its financial results in accordance with United States generally accepted accounting principles, or GAAP.  However, management believes that in order to properly understand the Company's short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP.  These items result from facts and circumstances that vary in frequency and/or impact on continuing operations.  Management also uses results of operations before such items to evaluate the operating performance of the Company and compare it against past periods, make operating decisions, and serve as a basis for strategic planning.  These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in the Company's ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of the Company's ongoing business with prior periods more difficult, obscure trends in ongoing operations or reduce management's ability to make useful forecasts.  Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance.  In addition, management understands that some investors and financial analysts find this information helpful in analyzing the Company's financial and operational performance and comparing this performance to its peers and competitors. Management defines "Non-GAAP Adjusted EBITDA" as the sum of GAAP net income (loss) before provision for taxes, acquisition-related expenses, total other (income) expense, stock-based compensation expense, depreciation and amortization, severance, gain on sale, loss on warrant, loss on extinguishment of debt, amortization of acquired intangibles, patent litigation and recall costs, contingent consideration, indemnification, asset and goodwill impairment charges.  Management considers this non-GAAP financial measure to be an important indicator of the Company's operational strength and performance of its business and a good measure of its historical operating trends, in particular the extent to which ongoing operations impact the Company's overall financial performance. Management defines "Non-GAAP Adjusted Net Income (loss)" as the sum of GAAP net income (loss) before provision for the gain on sale of asset, severance, transaction, patent litigation and recall costs, contingent consideration, indemnification, loss on extinguishment of debt and asset and goodwill impairment charges. Management considers this non-GAAP financial measure to be an important indicator of the Company's operational strength and performance of its business and a good measure of its historical operating trends, in particular the extent to which ongoing operations impact the Company's overall financial performance. Management excludes each of the items identified below from the applicable non-GAAP financial measure referenced above for the reasons set forth with respect to that excluded item: On occasion in the future, there may be other items, such as significant asset impairments, restructuring charges or significant gains or losses from contingencies that the Company may exclude if it believes that doing so is consistent with the goal of providing useful information to investors and management.


NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Alliance HealthCare Services, Inc. (NASDAQ: AIQ) (the “Company”, “Alliance”, “we” or “our”), a leading national provider of outsourced radiology, oncology and interventional services, announced today that Gregg Alan Dickerson, M.D., FACR, FACRO, has joined Alliance Cancer Centers in Greenville and Clarksdale and will be offering radiation oncology services to patients throughout Greenville, Clarksdale and the surrounding communities. “We are pleased to have Dr. Dickerson join the medical staff of the Alliance Cancer Centers in Greenville and Clarksdale,” said Candi Underwood, Site Administrator for the Alliance Cancer Centers in Greenville and Clarksdale. “Dr. Dickerson is a highly accomplished physician who brings over thirty years of radiation oncology experience to our cancer care treatment team and we are fortunate to have him care for the patients in our centers.” Gregg Alan Dickerson, M.D., FACR, FACRO, is a board certified radiation oncologist. Dr. Dickerson received his Bachelor of Arts with a double major in chemistry and biology from Indiana University in Bloomington, Indiana, and his medical degree from Indiana University School of Medicine in Indianapolis, Indiana. He completed his residency training in radiation oncology at the Bodine Center for Cancer Treatment at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania, where he also served as Chief Resident. In addition to his education and medical training, Dr. Dickerson spent 11 years serving our country as a flight surgeon in the Medical Corps of the Air National Guard, becoming a Major before being honorably discharged in 1996. Dr. Dickerson joined the Alliance Cancer Centers in Greenville and Clarksdale last October as an interim physician. “After many rewarding and productive years in Denver, Colorado, where I became highly specialized and accomplished for my work treating prostate cancer with radiosurgery, it was time to get ready for the next phase of my career,” said Dickerson. “It was at that time colleagues in the leadership of Alliance Oncology encouraged me to come to Mississippi to spend some time helping the good people of the Delta. What started off as a commitment for just a few months turned into a desire to continue caring for the dear people here and face the challenges that the spectrum of cancers they develop present. Joining the many other very compassionate physicians in the Delta and employing my advanced skills has been extremely satisfying and ultimately led to wanting to continue my work here.” Dr. Dickerson has been awarded over ten specialty honors and peer selected honors, including being ranked the number one radiation oncologist in Colorado in 2014 by HealthGrades.com. He also holds both military and civilian honors. He is a member of the American Society of Therapeutic Radiologists and Oncologists (ASTRO), the American College of Radiology (ACR), the American College of Radiation Oncology (ACRO), the Colorado Radiological Society, and the CyberKnife Society. For more information on Dr. Dickerson, or to schedule an appointment, please visit www.alliance-greenville-clarksdale.com. Alliance HealthCare Services (NASDAQ: AIQ) is a leading national provider of outsourced healthcare services to hospitals and providers. We also operate freestanding outpatient radiology, oncology and interventional services clinics, and Ambulatory Surgical Centers (“ASC”) that are not owned by hospitals or providers. Diagnostic radiology services are delivered through the Radiology Division (Alliance HealthCare Radiology), radiation oncology services are delivered through the Oncology Division (Alliance Oncology), and interventional and pain management services are delivered through the Interventional Division (Alliance Interventional). Alliance is the nation’s largest provider of advanced diagnostic mobile imaging services, an industry-leading operator of fixed-site imaging centers, and a leading provider of stereotactic radiosurgery nationwide. As of September 30, 2016, Alliance operated 619 diagnostic radiology and radiation therapy systems, including 112 fixed-site radiology centers across the country, and 32 radiation therapy centers and SRS facilities. With a strategy of partnering with hospitals, health systems and physician practices, Alliance provides quality clinical services for over 1,000 hospitals and other healthcare partners in 45 states, where approximately 2,400 Alliance Team Members are committed to providing exceptional patient care and exceeding customer expectations. For more information, visit www.alliancehealthcareservices-us.com.


News Article | March 2, 2017
Site: globenewswire.com

NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Dr. Alice V. Cheuk, Practice Chief of the Radiation Oncology Department at the James J. Peters VA Medical Center, has been selected to join the Physician Board at the American Health Council. She will be sharing her knowledge and expertise on Radiation Oncology, Cancer, and Radiation Therapy. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a0c2e9b5-54df-4b90-9a4e-b0df6ff85256 With over a decade of experience in the field of Radiation Oncology, Dr. Cheuk offers valuable insight in her role as the Practice Chief of Radiation Oncology at the James J. Peters VA Medical Center. Considered the oldest Veteran’s Affairs facility in New York City, the James J. Peters VA Medical Center is a teaching hospital utilizing state-of-the-art technology to provide comprehensive healthcare through education and research. The available services at the James J. Peters VA Medical Center range from primary care, tertiary care, and long-term care in areas of medicine, surgery, psychiatry, physical medicine and rehabilitation, neurology, oncology, dentistry, geriatrics, and extended care. As the Practice Chief of Radiation Oncology at the James J. Peters VA Medical Center since 2009, Dr. Cheuk’s day-to-day responsibilities include managing the care of cancer patients, overseeing and supervising the Radiation Oncology staff at the hospital, teaching residents from the Icahn School of Medicine at Mount Sinai, and serving on various hospital committees. In 2004, Dr. Cheuk earned her Medical Degree from the University of Maryland School of Medicine.  She completed an internship at The Reading Hospital and Medical Center in 2005 and a Radiation Oncology Residency at the University of Southern California/LAC+USC Medical Center in 2009 where she served as Chief Resident.  She is Board Certified in Radiation Oncology by the American Board of Radiology. Dr. Cheuk maintains affiliations with the American Society for Radiation Oncology (ASTRO), Society for Palliative Radiation Oncology (SPRO), Association of VA Hematology/Oncology (AVAHO), and is a member of the National VHA Palliative Radiotherapy Taskforce Group and Phi Beta Kappa. Dr. Cheuk’s desire to pursue the field of Radiation Oncology developed from her fascination with both oncology and technology. Looking back, she attributes her success to her persistence and strong work ethic. Among her plethora of professional accolades, Dr. Cheuk is most proud of the growth of the JJP VAMC Radiation Oncology Department during her tenure. Under her leadership, the department has increased staffing from 8.85 FTEE to 12.05 FTEE, acquired over 1 million dollars in new technology and upgrades to deliver state-of-the-art care to Veterans, revamped the practice to become ACR Accredited, and underwent a complete physical renovation to improve the comfort of patients.  Additionally, the department now has a standard rotation for Mount Sinai Radiation Oncology residents and is participating in cooperative group clinical trials. Her commitment to delivering the highest quality care to our Veterans has led to recognition with the Clinical Excellence Award for Customer Service by a JJP VAMC Outpatient Department in both 2013 and 2015. In her free time, Dr. Cheuk enjoys Broadway musicals, traveling, painting, drawing, writing, and karaoke. She volunteers at The Journey Church. Considering the future, Dr. Cheuk hopes for continual advancement of the Radiation Oncology Department and to help move the field of Radiation Oncology forward.


News Article | February 23, 2017
Site: www.acnnewswire.com

CASBAA, the Association for digital multichannel TV, content, platforms, advertising and video delivery in Asia, is pleased to announce its 4th OTT Summit, Asia's OTT industry marquee annual event. A series of panels comprised of some of the region's leading experts will explore in detail how traditional media is responding to the digital challenges of OTT. "We are delighted to be returning to Singapore for the fourth edition of CASBAA's OTT Summit," said Christopher Slaughter, CEO, CASBAA. "While traditional media incumbents remain dominant, there's no denying the growing impact of over-the-top (OTT) video services, and how they are transforming viewing habits throughout the region. We have been saying it for years, but it's now increasingly apparent that OTT is truly a big part of pay TV's future." The spectacular success, both critical and commercial, of such diverse video platforms as Netflix, Hooq and Spuul have established OTT services as real competitors to mainstream broadcasters. According to a survey by BCG, OTT services are growing by more than 20% annually and winning share over traditional TV.[1] Traditional media must respond fast to this existential crisis. The real challenge for incumbents is how to rethink their business strategies in light of such drastic industry transformation. Are legacy business models holding traditional media back as they contemplate the OTT challenge? CASBAA has convened a select field of industry thought leaders, senior executives and market practitioners, including: Ajit Mohan, CEO Hotstar Aravind Venugopal, VP - Media Partners Asia Winradit Kolasastraseni, SVP Innovation - Discovery Networks Asia Pacific Simon Vella, Head of Asia, MPP Global Oliver Wilkinson, MD, PwC Alan Soon, Founder & CEO, Splice Newsroom Shad Hashmi, VP - Digital Development, Global Markets & Operations Asia, BBC Worldwide Lam Swee Kim, CMO, Dimsum & Star Online Malaysia Prem Kamath, Deputy MD, A+E Networks Asia Alexandre Muller, MD APAC, TV5MONDE Jonas Engwall, CEO, RTL CBS Asia Virat Patel, MD, Pioneer Consulting Monica Bhatia, Regional Digital Director, APAC, Maxus Genny Yang, Group Account Director, Kantar Milward Brown David Schonfeld, Director Technical Operations, A+E Networks Asia Alex Merwin, VP International, SpotX Luke Gaydon, VP of OTT Solutions, Brightcove Yu-Chuang Kuek, Managing Director APAC, Netflix Ravi Vora, CMO, Hooq S Mohan, Co-Founder & COO, Spuul Lindsay Servian, Head of ONTAPtv.com, PCCW Global Maya Hari, MD - SEA & India, Twitter Tim Martin, CEO RugbyPass Michael Greco, VP APAC, Vindicia CK Lee, VP, Sports Business - Content Group, ASTRO Unmish Parthasarathi, Head of Digital Sales, International Cricket Council & Founder, Picture Board Craig Johnson, MD Media, SEA & India, Nielsen Priya Khatri, GM Sales & Business Development, SEA Eyeota Jay Shah, CEO, OpenDNA James Miner, CEO, Miner Labs Roger Harvey, Regional Director, Irdeto Mike Kerr, MD Asia, BEIN Joe Welch, SVP Government Relations APAC, 21st Century Fox Hian Goh, Partner, NSI Ventures Yinglan Tan, Venture Partner, Sequoia Marcel Fenez, President, Fenez Media The industry's essential platform to explore how OTT is transforming the broadcasting landscape, the CASBAA OTT Summit 2017 will take a deep dive on a range of topics, including trends in Asian viewership, whether OTT is a game changer in sports, how traditional media is adapting, the synergy between OTT and multiscreen, and how to use data as metrics for success. The CASBAA OTT Summit 2017 is a must for all those involved at the senior level in media and broadcasting, from content providers and broadcasters to investors and regulators. CASBAA OTT Summit 2017 is generously supported by Presenting Sponsor Brightcove, and Sponsors including Adobe, Diagnal, Irdeto, Mediamorph, MPP Global, PCCW Global and Vindicia. For more information about the CASBAA OTT Summit 2017 and to register for tickets, please visit http://casbaaevent.com/events/casbaa-ott-summit-2017/. [1] http://bit.ly/2dgHl2f About CASBAA CASBAA is the Asia Pacific region's largest non-profit media association, serving the multi-channel audio-visual content creation and distribution industry. Established in 1991, CASBAA has grown with the industry to include digital multichannel television, content, platforms, advertising, and video delivery. Encompassing some 500 million connections within a footprint across the region, CASBAA works to be the authoritative voice for multichannel TV; promoting even-handed and market-friendly regulation, IP protection and revenue growth for subscription and advertising, while promoting global best practices. For more information, visit www.casbaa.com. Contact:


News Article | February 22, 2017
Site: www.eurekalert.org

ALEXANDRIA, Va., February 22, 2017 - CancerLinQ LLC and the American Society for Radiation Oncology (ASTRO) are partnering to bring radiation oncology expertise to CancerLinQ and improve the care of cancer patients nationwide. ASTRO will provide guidance for the development of the CancerLinQ platform to ensure that the system captures more relevant patient data to drive actionable decision-making in cancer care, as well as to advance public policy and population health issues. ASTRO also will use insights from CancerLinQ Discovery to improve the care of patients receiving radiation therapy. Between half and two-thirds of all cancer patients receive radiation therapy, also known as radiotherapy, to cure cancer, control its spread and relieve symptoms such as pain. At present, however, important details about radiation dose and treatment schedule are often absent from the electronic health record systems used in many oncology practices. Through the partnership, experts will develop specialized indicators for radiation-related treatment outcomes and quality that can be incorporated into the CancerLinQ platform. Inclusion of these metrics will provide a much more complete and accurate characterization of the cancer care that patients are receiving, particularly for the many situations where radiation and chemotherapy are combined. "The addition of the nation's radiation oncologists is essential to ensuring CancerLinQ's capacity to improve patient care and can help both organizations achieve outcomes that are larger and more impactful than what either one could have achieved alone," said Kevin Fitzpatrick, Chief Executive Officer of CancerLinQ LLC. "With ASTRO, we are bringing the expertise of the nation's leading physicians who specialize in treating more than one million patients each year with radiation therapy." The partnership reflects CancerLinQ's goal to create a system that encompasses all of cancer care by bringing together expertise from throughout the cancer community, as well as ASTRO's mission to improve patient outcomes through research and education. "With the number of cancer patients rising each year, collaboration across the spectrum of cancer care has to be our reality rather than our goal," said Laura Thevenot, Chief Executive Officer of ASTRO. "By combining ASTRO's domain-specific knowledge with CancerLinQ's broad reach, we can help physicians and their patients be more informed as they navigate complex treatment decisions." As an official partnering organization of CancerLinQ, ASTRO will support professional member participation in the program, advocate for streamlined data integration between leading oncology electronic health systems, and strengthen CancerLinQ's role as a go-to resource for the healthcare community. ASTRO will have access to CancerLinQ Discovery, which generates specially curated sets of de-identified clinical data from the CancerLinQ platform for oncologists, researchers and analysts to create new clinical knowledge and improve patient outcomes. In addition, ASTRO will become a founding member of the CancerLinQ Oncology Leadership Council, a body of thought leaders and oncology-affiliated experts that advises the CancerLinQ Board of Governors. CancerLinQ is a powerful database--created by oncologists for oncologists--made up of vast amounts of usable, searchable, real-world cancer information. This big data initiative will allow users to see trends among millions of patients by analyzing cancer patient medical records, uncovering patterns that can improve patient care, and enabling doctors to compare their care against that of their peers and recommended guidelines. In addition to the radiation oncologists, CancerLinQ LLC--a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO)--is forging important strategic alliances with national leaders and organizations that play important roles across the entire care continuum that support high-quality care for patients, including professionals representing the entirety of the care team, government agencies, academic research institutions, life sciences, technology experts and advocacy organizations. CancerLinQ is supported in part through the Conquer Cancer Foundation, whose generous donors have helped make the system possible. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America; Chan Soon-Shiong Family Foundation; Genentech BioOncology; HELSINN; Janssen Oncology; Lilly; Raj Mantena, RPh; Novartis Oncology; Pfizer Oncology; Thomas G. Roberts, Jr., MD, and Susan M. DaSilva; and Susan G. Komen. CancerLinQ and CancerLinQ Discovery are projects of CancerLinQ LLC. For more information on how to participate or partner with CancerLinQ, please visit CancerLinQ.org. CancerLinQ LLC is a subsidiary of American Society of Clinical Oncology, Inc. established for the development and operation of the CancerLinQ initiative. CancerLinQ is a health information technology platform aimed at enhancing and improving the understanding and treatment of cancer. To learn more, visit http://www. . ASTRO is the premier radiation oncology society in the world, with more than 11,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals that specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology * Biology * Physics and Practical Radiation Oncology and Advances in Radiation Oncology; developed and maintains an extensive patient website, http://www. ; and created the Radiation Oncology Institute, a non-profit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit http://www. . Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO) is committed to making a world of difference in cancer care. As the world's leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at http://www. , explore patient education resources at http://www. , and follow us on Facebook, Twitter, LinkedIn, and YouTube.


News Article | February 16, 2017
Site: www.eurekalert.org

ARLINGTON, Va., February 16, 2017 -- The 2017 Multidisciplinary Thoracic Cancers Symposium, co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO) and The Society of Thoracic Surgeons (STS), will feature advances in surgery, radiation therapy, chemotherapy and novel molecular biologic therapies for thoracic malignancies such as lung cancer. The symposium will be held March 16-18, 2017, at the San Francisco Marriott Marquis. Press registration for the meeting is available online. Researchers from across the country will present findings on new combination therapies, targeted therapies, immunotherapy, next-generation sequencing, advanced radiation and surgical techniques, supportive care and guidelines for screening and prevention. Selected top-rated studies will be featured in news briefings held in-person and available online for registered reporters. Three keynote addresses will examine personalized surgical approaches, clinical trials in non-small cell lung cancer (NSCLC) and immunotherapeutic strategies to manage lung cancer. Keynote speakers include Valerie W. Rusch, MD, of Memorial Sloan Kettering Cancer Center in New York; Walter J. Curran, Jr., MD, of Winship Cancer Institute of Emory University in Atlanta; and Julie R. Brahmer, MD, of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore. Press Registration: Credentialed journalists from accredited news organizations are invited to attend and report on the 2017 Multidisciplinary Thoracic Cancers Symposium. Reporters registered by March 7, 2017, will receive the embargoed press kit prior to the meeting. The press policies and registration form are available online. News Briefings: Two news briefings will highlight top-rated abstracts selected from the general program. Briefings will be available live on-site in San Francisco and via webcast for registered press, with audio recordings and presenter slides posted online after each briefing. The final press program will be announced in late February. Press Office: Registered reporters are invited to check in at the on-site press office in the Foothill F room of the San Francisco Marriott Marquis, open during business hours on Thursday and Friday. More Information: More information is available at the 2017 Multidisciplinary Thoracic Cancers Symposium website, http://www. . ASTRO is the premier radiation oncology society in the world, with more than 11,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals that specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology * Biology * Physics and Practical Radiation Oncology and Advances in Radiation Oncology; developed and maintains an extensive patient website, http://www. ; and created the Radiation Oncology Institute, a non-profit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit http://www. . Founded in 1964, the American Society of Clinical Oncology (ASCO) is committed to making a world of difference in cancer care. As the world's leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at http://www. , explore patient education resources at http://www. , and follow us on Facebook, Twitter, LinkedIn, and YouTube. Founded in 1964, The Society of Thoracic Surgeons is a not-for-profit organization representing approximately 7,200 cardiothoracic surgeons, researchers, and allied health care professionals worldwide who are dedicated to ensuring the best possible outcomes for surgeries of the heart, lung, and esophagus, as well as other surgical procedures within the chest. The Society's mission is to enhance the ability of cardiothoracic surgeons to provide the highest quality patient care through education, research, and advocacy.


News Article | February 13, 2017
Site: globenewswire.com

DURHAM, N.C., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that the company will present at the 2017 Genitourinary Cancers Symposium being held February 16-18 at the Rosen Shingle Creek in Orlando, FL. Irina Tcherepanova, Ph.D., senior director of research and development for Argos, will review a poster titled, “Development of a novel immunotherapy for muscle invasive bladder cancer (MIBC),” during Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer on Saturday, February 18 from 7:00-7:55am ET and 11:30am-1:00pm ET. The 2017 Genitourinary Cancers Symposium is a three-day scientific and educational meeting cosponsored by the American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO), and Society of Urologic Oncology (SUO). For more information, visit http://gucasym.org/. About the Arcelis® Technology Platform Arcelis® is a precision immunotherapy technology that captures both mutated and variant antigens that are specific to each patient’s individual disease. It is designed to overcome immunosuppression by producing a specifically targeted, durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to the treatment of a wide range of different cancers and infectious diseases, and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies. The Arcelis® process uses only a small disease sample or biopsy as the source of disease-specific antigens, and the patient’s own dendritic cells, which are optimized from cells collected by a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease-specific antigens. These activated, antigen-loaded dendritic cells are then formulated with the patient’s plasma, and administered via intradermal injection as an individualized immunotherapy. About Argos Therapeutics Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, rocapuldencel-T, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). In addition, rocapuldencel-T is being studied in Phase 2 investigator-initiated clinical trials as neoadjuvant therapy for renal cell carcinoma (RCC) and for the treatment of non-small cell lung cancer (NSCLC). Argos is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated Phase 2 clinical trial aimed at HIV eradication in adult patients. Forward Looking Statements Any statements in this press release about Argos’ future expectations, plans and prospects, including statements about the expected use of the leased manufacturing space, Argos’ financial prospects, future operations and sufficiency of funds for future operations, clinical development of Argos’ product candidates, expectations regarding future clinical trials and future expectations and plans and prospects for Argos and other statements containing the words "believes," "anticipates," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," “may,” "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Argos' cash resources will be sufficient to fund its continuing operations for the periods anticipated; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Argos' product candidates will advance through the clinical trial process on a timely basis; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Argos' product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; whether Argos can successfully establish commercial manufacturing operations on a timely basis or at all; and other factors discussed in the "Risk Factors" section of Argos’ Form 10-Q for the quarter ended September 30, 2016, which is on file with the SEC, and in other filings Argos makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent Argos’ views as of the date hereof. Argos anticipates that subsequent events and developments will cause Argos’ views to change. However, while Argos may elect to update these forward-looking statements at some point in the future, Argos specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Argos’ views as of any date subsequent to the date hereof.


Updated ASTRO guideline upholds standard of care and emphasizes safety and efficacy of radiation treatment ARLINGTON, VA--(Marketwired - February 14, 2017) - The American Society for Radiation Oncology (ASTRO) recently published an updated clinical guideline that underscores the safety and effectiveness of palliative radiation therapy (RT) for treating painful bone metastases. Based on recent clinical trial data, the guideline recommends optimal RT dosing schedules for pain relief, including options for re-treatment. The guideline, "Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline," is available as a free access article in Practical Radiation Oncology, ASTRO's clinical practice journal. When cancer cells spread through the body and invade a patient's bones, these new lesions are known as bone metastases. Many different types of cancer can spread to the skeletal system, including breast, prostate, lung and rectal cancers, and bone metastases may occur months or even years after an original cancer diagnosis. Treatment of these malignancies aims to provide relief for symptoms, such as pain and spinal cord compression, and to suppress local disease. Radiation therapy, also known as radiotherapy, is a safe and effective option to relieve symptoms associated with bone metastases. The updated guideline maintains the four previously recommended dosing schedules for external RT to treat previously unirradiated tumors: a single 8 Gray (Gy) fraction of RT; 20 Gy administered in five fractions; 24 Gy in six fractions; or 30 Gy in 10 fractions. Research indicates that patients experience similar pain relief and toxicity rates with each of the fractionation options. Although clinical trials have cited higher retreatment rates for patients who received single-fraction RT, the convenience of this option may make it the optimal choice for patients with limited life expectancy. A recent analysis of clinical trial data published in JAMA Oncology recommended that "a single 8-Gy radiotherapy dose for bone metastases should be offered to all patients, even those with poor survival." Greater adoption of the single-fraction approach -- which requires only one visit -- also may reduce the disparity between the number of patients who would benefit from this therapy and the markedly small number who actually receive it. Surveys of palliative care professionals indicate that the vast majority consider RT an important and effective component of hospice care but do not actually refer many of their patients for the therapy. In one study, for example, 88 percent of hospice professionals said that painful bone metastases merited referral for palliative RT, but only 3 percent of hospice patients nationwide actually received the treatment. Barriers including cost, transportation and length of treatment were cited as key reasons for underutilization. "Decades of research and many clinical trials have established that radiation therapy provides safe, effective and quick pain relief for patients suffering from bone metastases," said Stephen Lutz, MD, FASTRO, chair of the task force that developed the guideline update and a radiation oncologist at Blanchard Valley Regional Health Center in Findlay, Ohio. "Moreover, this relief can be achieved in as little as a single fraction, which alleviates the additional burdens of time, travel and cost for the patient." In addition to primary treatment, the guideline also addresses retreatment of bone metastases. It recommends that reirradiation should be considered if patients experience recurrent or persistent pain more than a month following external-beam radiation therapy (EBRT) to treat peripheral bone metastases or spine lesions. Research demonstrates moderate effectiveness for reirradiation; a 2014 systematic review and meta-analysis found an overall pain response rate of 58 percent. The guideline also considers the role of advanced RT techniques, such as stereotactic body radiation therapy (SBRT), in primary treatment and retreatment of painful bone metastases. SBRT uses sophisticated imaging techniques to deliver a highly targeted, escalated dose of radiation to the tumor and to limit damage to the surrounding tissue. This precise targeting is particularly important for tumor sites near multiple surrounding organs, such as the lung or prostate, or complex sites, such as the neural system. While emerging evidence points to the potential of SBRT to treat spinal metastases, research in this area is limited compared with the data supporting EBRT. Accordingly, the guideline recommends that the use of advanced RT techniques for primary treatment or retreatment of spinal lesions should be considered only in clinical trial or registry settings. It also recommends that physicians consult the current ASTRO white paper on SBRT to inform their treatment decisions. The guideline was based on a systematic literature review of studies published from December 2009, the last date that was searched for the original 2011 guideline, through January 2015. A total of 414 abstracts were retrieved from PubMed, and the 56 articles that met inclusion criteria (including 20 randomized controlled trials, 32 nonrandomized prospective studies and four meta-analyses or pooled analyses) were abstracted into evidence tables and evaluated by an eight-member expert panel of radiation oncologists and topic experts in metastatic disease. The clinical practice statement was approved by ASTRO's Board of Directors following a period of public comment. For a copy of the complete guideline, contact ASTRO's media relations team at press@astro.org or 703-286-1600, or download it online. Learn more about Practical Radiation Oncology at www.practicalradonc.org. ASTRO is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals that specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology · Biology · Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit www.astro.org.


News Article | February 16, 2017
Site: www.businesswire.com

CHICAGO--(BUSINESS WIRE)--Motorola Solutions (NYSE: MSI) joined law enforcement, fire and emergency response personnel in using the Los Angeles Regional Interoperable Communications System’s (LA-RICS) private 4G broadband network during the 2017 Tournament of Roses Parade, adding new communications capabilities and elevating situational awareness for first responders. Motorola Solutions built the network for LA-RICS, and it remains the largest U.S. broadband network dedicated for public safety. During the parade the network provided the latest long term evolution (LTE)-empowered tools for many of the 1,500 responders who protected more than 750,000 onlookers in Pasadena, California, spread over a 5.5-mile parade route. Building on last year’s successful broadband demonstration during the parade, LA-RICS and Motorola Solutions deployed a wide range of technology for this year’s parade. High-definition camera feeds, broadband-equipped handheld devices and software applications worked together to enable improved information sharing and communication through voice, data, pictures and video. “Protecting this parade brought together public safety agencies from around the Los Angeles County region, and our broadband network provided a strong backbone to let them do their jobs even more effectively,” said John Radeleff, interim executive director, LA-RICS. “This deployment helped public safety teams stay in touch no matter what type of radio or device they used, helped the command center staff keep close track of resources and personnel, and ultimately kept the parade-watching public safer than ever before.” Motorola Solutions supported LA-RICS, the Los Angeles County Sheriff’s Department and Los Angeles County Fire Department along with other local and federal law enforcement and public safety agencies that jointly deployed to protect one of the region’s largest public events. LA-RICS noted the successful deployment in its own news release. Participants used Motorola Solutions APX™-series radios on an ASTRO® 25 land mobile radio (LMR) network along with the broadband functions of LA-RICS to establish interoperable communications and seamless data sharing. Public safety responders also used Motorola Solutions’ LEX L10 Mission Critical LTE Handheld devices, VML 750 trunk-mount modems and a variety of software tools on the network to enhance situational awareness at the parade. Deputies and officers on the parade route communicated quickly and clearly in specific talkgroups using WAVE™ 5000 Work Group Communications software that seamlessly and securely linked LMR and LTE devices across the LA-RICS network. WAVE’s push-to-talk function allowed agencies to easily customize talkgroups for each parade security zone, whether responders were using broadband smartphones, LMR radios or other devices. “As the country moves closer to starting construction on a national broadband public safety network, we understand the advantages public safety agencies can achieve using broadband technology during events such as LA-RICS deploying at the Rose Parade,” said Travis Boettcher, vice president of sales, Motorola Solutions. “Our software, managed services and LTE-enabled devices help public safety agencies realize the immense potential broadband has to both keep first responders safe and help them do their jobs even more effectively.” The current LA-RICS system, built with Motorola Solutions strategic partner Ericsson, has more than 70 LTE towers and will have a growing number of LMR sites to boost the overall system’s appeal to public safety agencies as more towers are added. LA-RICS represents the largest of the Early Builder projects that are part of the First Responder Network Authority (FirstNet). As the prime contractor for LA-RICS, Motorola Solutions continues its global leadership in creating public safety broadband networks that complement existing LMR infrastructure. Read LA-RICS’ release on the deployment Learn more about the LEX L10 here and here. Learn more about the VML 750 here. Learn more about LTE infrastructure here. Learn more about WAVE here. Motorola Solutions (NYSE: MSI) creates innovative, mission-critical communication solutions and services that help public safety and commercial customers build safer cities and thriving communities. For ongoing news, visit www.motorolasolutions.com/newsroom or subscribe to a news feed. MOTOROLA, MOTOROLA SOLUTIONS and the Stylized M Logo are trademarks or registered trademarks of Motorola Trademark Holdings, LLC and are used under license. All other trademarks are the property of their respective owners. ©2017 Motorola Solutions, Inc. All rights reserved.

Loading ASTRO collaborators
Loading ASTRO collaborators